|
1
|
Moccia A, Schär S, Hayoz S, Pirosa M, Taverna C, Novak U, Kimby E, Ghielmini M, Zucca E. PREDICTIVE VALUE OF POD24 VALIDATION IN FOLLICULAR LYMPHOMA PATIENTS INITIALLY TREATED WITH CHEMOTHERAPY-FREE REGIMENS IN A POOLED ANALYSIS OF THREE RANDOMIZED TRIALS OF THE SWISS GROUP FOR CLINICAL CANCER RESEARCH (SAKK). Hematol Oncol 2019. [DOI: 10.1002/hon.73_2629] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- A. Moccia
- Department of Medical Oncology; Oncology Institute of Southern Switzerland and SAKK Coordinating Center; Bellinzona Switzerland
| | - S. Schär
- Coordinating Center; SAKK; Bern Switzerland
| | - S. Hayoz
- Coordinating Center; SAKK; Bern Switzerland
| | - M. Pirosa
- Department of Medical Oncology; Oncology Institute of Southern Switzerland and SAKK Coordinating Center; Bellinzona Switzerland
| | - C. Taverna
- Division of Medical Oncology; Kantonsspital Münsterlingen and SAKK Coordinating Center; Münsterlingen Switzerland
| | - U. Novak
- Department of Medical Oncology; Inselspital / Bern University Hospital and SAKK Coordinating Center; Bern Switzerland
| | - E. Kimby
- Division Unit of Hematology; Karolinska Institutet, Department of Medicine at Huddinge; Stockholm Sweden
| | - M. Ghielmini
- Department of Medical Oncology; Oncology Institute of Southern Switzerland and SAKK Coordinating Center; Bellinzona Switzerland
| | - E. Zucca
- Department of Medical Oncology; Oncology Institute of Southern Switzerland, SAKK Coordinating Center and Bern University Hospital; Bellinzona Switzerland
| |
Collapse
|
|
2
|
Ceriani L, Pirosa M, Stathis A, Gritti G, Ruberto T, Bruno A, Moccia A, Rambaldi A, Ferrari S, Giovannella L, Hayoz S, Mazzucchelli L, Dirnhofer S, Mamot C, Zucca E. INTEGRATION BETWEEN METABOLIC TUMOUR VOLUME AND METABOLIC HETEROGENEITY PREDICTS OUTCOME OF DLBCL LYMPHOMA PATIENTS IN THE SAKK 38/07 STUDY COHORT. Hematol Oncol 2019. [DOI: 10.1002/hon.47_2629] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- L. Ceriani
- Nuclear Medicine and PET-CT centre; Imaging Institute of Southern Switzerland; Bellinzona Switzerland
| | - M. Pirosa
- Division of Medical Oncology; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | - A. Stathis
- Division of Medical Oncology; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | - G. Gritti
- Hematology Unit; ASST Papa Giovanni XXIII; Bergamo Italy
| | - T. Ruberto
- Nuclear Medicine and PET-CT centre; Imaging Institute of Southern Switzerland; Bellinzona Switzerland
| | - A. Bruno
- Department of Nuclear Medicine; ASST Papa Giovanni XXIII; Bergamo Italy
| | - A. Moccia
- Division of Medical Oncology; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | - A. Rambaldi
- Hematology Unit; ASST Papa Giovanni XXIII; Bergamo Italy
| | - S. Ferrari
- Hematology Unit; ASST Papa Giovanni XXIII; Bergamo Italy
| | - L. Giovannella
- Nuclear Medicine and PET-CT centre; Imaging Institute of Southern Switzerland; Bellinzona Switzerland
| | - S. Hayoz
- Coordinating Center; SAKK; Bern Switzerland
| | | | - S. Dirnhofer
- Institute of Medical Genetics and Pathology; University Hospital; Basel Switzerland
| | - C. Mamot
- Medical Oncology; Cantonal Hospital; Aarau Switzerland
| | - E. Zucca
- Division of Medical Oncology; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| |
Collapse
|